Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 4, 2013, Pages

  Rajagopalan, Viswanathan ^a   Zhao, Mingming ^a   Reddy, Sushma ^a   Fajardo, Giovanni ^a   Wang, Xuejun ^b   Dewey, Shannamar ^c   Gomes, Aldrin V ^c   Bernstein, Daniel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac hypertrophy; Heart failure; Proteasome; Right ventricle; Ubiquitin

Indexed keywords

PROTEASOME; PROTEIN BAX; PROTEIN BCL 2; SMURF1 E3 UBIQUITIN LIGASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UCHL1 DEUBIQUITINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL;

CARDIAC HYPERTROPHY; HEART FAILURE; PROTEASOME; RIGHT VENTRICLE; UBIQUITIN;

ANIMALS; APOPTOSIS; CONSTRICTION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC THERAPY; HEART FAILURE; HEMODYNAMICS; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MICE; MICE, TRANSGENIC; MYOCARDIUM; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PULMONARY ARTERY; SIGNAL TRANSDUCTION; TIME FACTORS; UBIQUITIN; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84881646021     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00771.2012     Document Type: Article

References (75)

1. Asimaki A, Syrris P, Wichter T, Matthias P, Saffitz JE, McKenna WJ. A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 81: 964-973, 2007.
2. Baker TA, Geng Q, Romero J, Picken MM, Gamelli RL, Majetschak M. Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation. Biochem Biophys Res Commun 401: 548-553, 2010.
3. Balasubramanian S, Mani S, Shiraishi H, Johnston RK, Yamane K, Willey CD, Cooper IV G, Tuxworth WJ, Kuppuswamy D. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J Mol Cell Cardiol 41: 669-679, 2006.
4. Bernstein D, Webber S. New directions in basic research in hypertrophy and heart failure: relevance for pediatric cardiology. Prog Pediatr Cardiol 32: 5-9, 2011.
5. Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P, Khan M, Ovaa H, Terracciano CM, Barton PJ, Yacoub MH, Evans PC. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79: 472-480, 2008.
6. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 163: 1663-1675, 2003.
7. + currents in adult mouse ventricles. J Physiol 559: 103-120, 2004.
8. Bulteau AL, Szweda LI, Friguet B. Age-dependent declines in proteasome activity in the heart. Arch Biochem Biophys 397: 298-304, 2002.
9. Cai ZP, Shen Z, Van Kaer L, Becker LC. Ischemic preconditioninginduced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. FASEB J 22: 4248-4257, 2008.
10. Calise J, Powell SR. The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol 304: H337-H349, 2013.
11. Carrier L. Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail. Cardiovasc Res 88: 389-390, 2010.
12. Chen B, Ma Y, Meng R, Xiong Z, Zhang C, Chen G, Zhang A, Dong Y. MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals. Acta Biochim Biophys Sin (Shanghai) 42: 253-258, 2010.
13. Chen Q, Liu JB, Horak KM, Zheng H, Kumarapeli AR, Li J, Li F, Gerdes AM, Wawrousek EF, Wang X. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 97: 1018-1026, 2005.
14. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. Ubiquitinindependent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell 26: 843-852, 2007.
15. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/ PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349-38352, 2001.
16. Churchill EN, Ferreira JC, Brum PC, Szweda LI, Mochly-Rosen D. Ischaemic preconditioning improves proteasomal activity and increases the degradation of OE¥PKC during reperfusion. Cardiovasc Res 85: 385-394, 2010.
17. Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 66: S7-S19, 2006.
18. Dantuma NP, Lindsten K. Stressing the ubiquitin-proteasome system. Cardiovasc Res 85: 263-271, 2010.
19. Day SM, Divald A, Wang P, Davis F, Bartolone S, Jones R, Powell SR. Impaired assembly and post-translational regulation of 26S proteasome in human end stage heart failure. Circ Heart Fail 6: 544-549, 2013.
20. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114: 1821-1828, 2006.
21. Divald A, Kivity S, Wang P, Hochhauser E, Roberts B, Teichberg S, Gomes AV, Powell SR. Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 106: 1829-1838, 2010.
22. Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, Marcotte F, Mercier LA. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 112: 2411-2416, 2005.
23. Drews O, Tsukamoto O, Liem D, Streicher J, Wang Y, Ping P. Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ Res 107: 1094-1101, 2010.
24. Dupont S, Inui M, Newfeld SJ. Regulation of TGF-beta signal transduction by mono-and deubiquitylation of Smads. FEBS Lett 586: 1913-1920, 2012.
25. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138: 396-397, 2007.
26. Ferrington DA, Husom AD, Thompson LV. Altered proteasome structure, function, and oxidation in aged muscle. FASEB J 19: 644-646, 2005.
27. Gao G, Zhang J, Si X, Wong J, Cheung C, McManus B, Luo H. Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice. Am J Physiol Heart Circ Physiol 295: H401-H408, 2008.
28. Gomes AV, Waddell DS, Siu R, Stein M, Dewey S, Furlow JD, Bodine SC. Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. FASEB J 26: 2986-2999, 2012.
29. Gomes AV, Waddell DS, Siu R, Stein M, Dewey S, Furlow JD, Bodine SC. Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. FASEB J 26: 2986-2999, 2012.
30. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, Stefani E, Ping P. Contrasting proteome biology and functional heterogeneity of the 20S proteasome complexes in mammalian tissues. Mol Cell Proteomics 8: 302-315, 2009.
31. Hedhli N, Depre C. Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 85: 321-329, 2010.
32. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, Liu H, Tian Y, Gao S, Madura K, Vatner SF, Depre C. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 295: H1385-H1393, 2008.
33. Hwee DT, Gomes AV, Bodine SC. Cardiac proteasome activity in muscle ring finger-1 null mice at rest and following synthetic glucocorticoid treatment. Am J Physiol Endocrinol Metab 301: E967-E977, 2011.
34. Kaufman BD, Desai M, Reddy S, Osorio JC, Chen JM, Mosca RS, Ferrante AW, Mital S. Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Card Fail 14: 760-767, 2008.
35. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758, 2001.
36. Kloss A, Meiners S, Ludwig A, Dahlmann B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc Res 85: 367-375, 2010.
37. Kondo RP, Dederko DA, Teutsch C, Chrast J, Catalucci D, Chien KR, Giles WR. Comparison of contraction and calcium handling between right and left ventricular myocytes from adult mouse heart: a role for repolarization waveform. J Physiol 571: 131-146, 2006.
38. Kraft C, Peter M, Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol 12: 836-841, 2010.
39. Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Mol Cell Biol 25: 3173-3181, 2005.
40. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP, Wilson SM, King RW, Finley D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467: 179-184, 2010.
41. Li J, Horak KM, Su H, Sanbe A, Robbins J, Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/ reperfusion injury in mice. J Clin Invest 121: 3689-3700, 2011.
42. Li J, Powell SR, Wang X. Enhancement of proteasome function by PA28α overexpression protects against oxidative stress. FASEB J 25: 883-893, 2011.
43. Li YF, Wang X. The role of the proteasome in heart disease. Biochim Biophys Acta 1809: 141-149, 2011.
44. Lindqvist P, Henein M, Kazzam E. Right ventricular outflow-tract fractional shortening: an applicable measure of right ventricular systolic function. Eur J Echocardiogr 4: 29-35, 2003.
45. 1 pathway. Biochem Pharmacol 81: 1228-1236, 2011.
46. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C, Baumann G, Stangl V, Stangl K. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 51: 302-308, 2008.
47. Otsuka K, Terasaki F, Shimomura H, Tsukada B, Horii T, Isomura T, Suma H, Shibayama Y, Kitaura Y. Enhanced expression of the ubiquitin-proteasome system in the myocardium from patients with dilated cardiomyopathy referred for left ventriculoplasty: an immunohistochemical study with special reference to oxidative stress. Heart Vessels 25: 474-484, 2010.
48. Portbury AL, Ronnebaum SM, Zungu M, Patterson C, Willis MS. Back to your heart: ubiquitin proteasome system-regulated signal transduction. J Mol Cell Cardiol 52: 526-537, 2012.
49. Predmore JM, Wang P, Davis F, Bartolone S, Westfall MV, Dyke DB, Pagani F, Powell SR, Day SM. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 121: 997-1004, 2010.
50. Razeghi P, Taegtmeyer H. Cardiac remodeling: UPS lost in transit. Circ Res 97: 964-966, 2005.
51. Reddy S, Zhao M, Hu DQ, Fajardo G, Hu S, Ghosh Z, Rajagopalan V, Wu JC, Bernstein D. Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics 44: 562-575, 2012.
52. Reddy SZM, Hu DQ, Fajardo G, Katznelson E, Punn R, Spin JM, Chan FP, Bernstein D. Physiologic and molecular characterization of a murine model of right ventricular volume overload. Am J Physiol Heart Circ Physiol 304: H1314-H1327, 2013.
53. Sanchez NS, Barnett JV. TGFbeta and BMP-2 regulate epicardial cell invasion via TGFbetaR3 activation of the Par6/Smurf1/RhoA pathway. Cell Signal 24: 539-548, 2012.
54. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY, Pediatric Carvedilol Study Group. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298: 1171-1179, 2007.
55. Sohns W, van Veen TA, van der Heyden MA. Regulatory roles of the ubiquitin-proteasome system in cardiomyocyte apoptosis. Curr Mol Med 10: 1-13, 2010.
56. Su H, Wang X. The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res 85: 253-262, 2010.
57. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 76: 725-746, 1998
58. Takami Y, Nakagami H, Morishita R, Katsuya T, Cui TX, Ichikawa T, Saito Y, Hayashi H, Kikuchi Y, Nishikawa T, Baba Y, Yasuda O, Rakugi H, Ogihara T, Kaneda Y. Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol 27: 2184-2190, 2007.
59. Tang M, Li J, Huang W, Su H, Liang Q, Tian Z, Horak KM, Molkentin JD, Wang X. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res 88: 424-433, 2011.
60. Tian Z, Zheng H, Li J, Li Y, Su H, Wang X. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res 111: 532-542, 2012.
61. Townsend TA, Wrana JL, Davis GE, Barnett JV. Transforming growth factor-beta-stimulated endocardial cell transformation is dependent on Par6c regulation of RhoA. J Biol Chem 283: 13834-13841, 2008.
62. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H, Liao Y, Okazaki H, Asai M, Hirata A, Fujita M, Asano Y, Yamazaki S, Asanuma H, Hori M, Kitakaze M. Depression of proteasome activities during the progression of cardiac dysfunction in pressureoverloaded heart of mice. Biochem Biophys Res Commun 340: 1125-1133, 2006.
63. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121, 2001.
64. Ulrich HD, Walden H. Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Biol 11: 479-489, 2010.
65. Umar SDS, Lorga A, Gomes A, Eghbali M. Severe pulmonary hypertension and right ventricular dysfunction in rats are associated with changes in ubiquitin proteasome system (Abstract). Circulation 124: A14660, 2011.
66. Urashima T, Zhao M, Wagner R, Fajardo G, Farahani S, Quertermous T, Bernstein D. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol 295: H1351-H1368, 2008.
67. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a posttranslational modification at the edge of life and death. Nat Rev Mol Cell Biol 12: 439-452, 2011.
68. 1-adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol 298: H913-H920, 2010.
69. Wang S, Sun A, Li L, Zhao G, Jia J, Wang K, Ge J, Zou Y. Upregualtion of BMP-2 antagonizes TGF-beta1/ROCK-enhanced cardiac fibrotic signaling through activating of Smurf1/Smad6 complex. J Cell Mol Med 16: 2301-2310, 2012.
70. Wang X, Li J, Zheng H, Su H, Powell SR. Proteasome functional insufficiency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol 301: H2207-H2219, 2011.
71. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3: 208-216, 2003.
72. 1 Integrin and organized actin filaments facilitate cardiomyocytespecific RhoA-dependent activation of the skeletal alpha-actin promoter. FASEB J 15: 785-796, 2001.
73. Young GW, Wang Y, Ping P. Understanding proteasome assembly and regulation: importance to cardiovascular medicine. Trends Cardiovasc Med 18: 93-98, 2008.
74. Zhang Z, Krutchinsky A, Endicott S, Realini C, Rechsteiner M, Standing KG. Proteasome activator 11S REG or PA28: recombinant REG alpha/REG beta hetero-oligomers are heptamers. Biochemistry 38: 5651-5658, 1999.
75. Zhao M, Fajardo G, Urashima T, Spin JM, Poorfarahani S, Rajagopalan V, Huynh D, Connolly A, Quertermous T, Bernstein D. Cardiac pressure overload hypertrophy is differentially regulated by β-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 301: H1461-H1470, 2011.